Stroke is One of the Top Three Causes of Death and Its Incidence in the Seven Major Markets is Expected to Increase in the Next Ten Years
Posted on: Wednesday, 18 June 2008, 06:00 CDT
Research and Markets (http://www.researchandmarkets.com/research/f2017e/pipeline_insight) has announced the addition of the "Pipeline Insight: Acute Stroke: Commercial Risk Offsets High Unmet Need" report to their offering.
Introduction
Stroke is one of the top three causes of death and its incidence in the seven major markets is expected to increase in the next ten years because of an aging population. Long term disability caused by stroke is a major economic burden on healthcare systems, current treatment options are limited and general awareness of stroke is poor.
Scope
Analysis of patient potential, unmet needs and clinical trial design in acute stroke; Overview of drugs in late- and early-stage clinical development; with analysis of key companies involved in the R&D pipeline; Detailed profiles of key compounds in development for use in acute stroke, with forecasts of drug revenues to 2017; Review of the recent failures in acute stroke (NXY-059 and NovoSeven)
Highlights
In the setting of acute stroke, a patients treatment options and recovery prospects are a function of time. Therefore any delay related to the time-to-treatment constitutes a resistor to market entry and uptake for stroke therapies in the acute care hospital setting. The R&D landscape is shaped by the need to minimize the commercial risk associated with developing drugs for the acute-care stroke market - the majority of the companies contribute only one candidate drug to the acute stroke pipeline. The future prognosis for the acute stroke therapy is marred by the long list of failures, especially of neuroprotectants. Thrombolytics are also plagued by shortcomings in trial design, which result either in discontinuation of the drugs, or prolonged development that leads in its turn to the low credibility of the compounds.
Reasons to Purchase
Understand clinical and environmental unmet needs in the acute stroke market based on key opinion leader comments Benchmark key late-stage pipeline products against the current market leader and class comparator; Assess the 7 major markets (US, Japan, 5 major EU) sales forecasts of late-stage pipeline drugs and examine their clinical and commercial potential.
Key Topics Covered:
ABOUT US HEALTHCARE CHAPTER 1 EXECUTIVE SUMMARY CHAPTER 2 PIPELINE OVERVIEW AND DYNAMICS CHAPTER 3 PATIENT POTENTIAL CHAPTER 4 R&D APPROACH CHAPTER 5 LATE-STAGE DRUG ANALYSIS & FORECASTS: VASOPROTECTIVE THERAPIES CHAPTER 6 LATE-STAGE DRUG ANALYSIS & FORECASTS: REPERFUSION THERAPIES CHAPTER 7 OTHER ACUTE STROKE DRUGS APPENDIX A APPENDIX B List of Tables List of Figures
For more information visit http://www.researchandmarkets.com/research/f2017e/pipeline_insight
Source: Datamonitor
Source: Business Wire
Related Articles
- Cancer - Gastrointestinal (Stomach) Cancer Report Provides The User With Real Detail On Drug Pipelines, By Company And By Stage
- Pipeline And Commercial Insight Urinary Incontinence Provides An Overview Of Key Marketed Brands Late And Early Stage Pipeline Drugs And Cell Therapies
- Current Pharmaceutical Pipelines Are Testimony to the Intensity of Breast Cancer Drug Development With At Least 50 Investigational Drugs/Drug Combinations in Clinical Development
- Central Nervous System Stroke Drug Pipeline Report Provides the User With Real Details on Stroke Drug Pipelines By Company and By Stage
- Research and Markets: Examine the Top 20 Companies in Late and Early Stage of Glaucoma Projects Inside ''Ophthalmology and Optometry - Glaucoma Drug Pipeline Report''
- The Emerging Drug Targets Outlook: An Analysis of Novel Molecular Targets to Develop Innovative New Therapeutics
- BioLineRx Raises an Additional $9 Million and Advances Pipeline of Drug Candidates Toward Clinical Trials
- Welsh Pupils' Key Stage Assessments Improve
- Kinex Pharmaceuticals Selects Lead Drug Candidate for Clinical Development in Oncology
- Obesity Boosts Drug Spending; Mayo Clinic Study Says Extra Weight Increases Prescription Tab for Men
 |
 |
User Comments (0)
RSS Feeds